Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05136885 | HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose | PHASE2 | COMPLETED | 161 | — | — | Feb 21, 2022 | Aug 25, 2023 | May 14, 2025 | 1 | United States |
Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.
Mortality is defined as death or death equivalent. A participant is determined to meet the criteria of death equivalent if permanent assisted ventilation (PAV) is used for more than 22 hours per day for more than seven days in a row. The rate of mortality was estimated from a Bayesian shared-parametric model that assumed exponentially distributed survival times.
| Arm | Type | Description |
|---|---|---|
| SLS-005 | EXPERIMENTAL | SLS-005 is administered via infusion once weekly for 24 weeks. |
| Matching Placebo | PLACEBO_COMPARATOR | Matching placebo is administered via infusion once weekly for 24 weeks. |
| Name | Type | Description |
|---|---|---|
| SLS-005 | DRUG | Administration: Infusion Dose: 0.75 g/kg weekly |
| Matching Placebo | DRUG | Administration: Infusion Dose: equivalent weight-based volume as described for trehalose |
Inclusion Criteria: * No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683). Exclusion Criteria: * The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683). 1. Curre...